# Vaxxinity (stock symbol: VAXX) Logo in transparent PNG and SVG formats

## Vaxxinity Logo large

### Vaxxinity Logo large Download PNG (28.63 KB)

![Vaxxinity Logo large Download PNG (28.63 KB)](/img/orig/VAXX_BIG-4d8eb717.png)

### Vaxxinity Logo large Download SVG (2.84 KB)

![Vaxxinity Logo large Download SVG (2.84 KB)](/img/orig/VAXX_BIG-673b1c0a.svg)

## Vaxxinity Logo icon format

### Vaxxinity Logo icon format Download PNG (31.67 KB)

![Vaxxinity Logo icon format Download PNG (31.67 KB)](/img/orig/VAXX-78c30ce1.png)

### Vaxxinity Logo icon format Download SVG (791 Bytes)

![Vaxxinity Logo icon format Download SVG (791 Bytes)](/img/orig/VAXX-bbc860ef.svg)

## Vaxxinity Logo large for dark backgrounds

### Vaxxinity Logo large for dark backgrounds Download PNG (29.39 KB)

![Vaxxinity Logo large for dark backgrounds Download PNG (29.39 KB)](/img/orig/VAXX_BIG.D-777a4dc7.png)

### Vaxxinity Logo large for dark backgrounds Download SVG (2.84 KB)

![Vaxxinity Logo large for dark backgrounds Download SVG (2.84 KB)](/img/orig/VAXX_BIG.D-d9d3604c.svg)

## About Vaxxinity

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

1. Website domain: vaxxinity.com
2. Employees: 89
3. Marketcap: $0.26 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
